ReviewFuture cardiology2025
Early diagnosis of cardiac involvement in Anderson-Fabry disease using cardiac MRI parameters.
Review in Future cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anderson-Fabry disease (AFD) is a rare, X-linked, lysosomal storage disorder caused by the absence or deficiency of alpha-galactosidase A activity, leading to the progressive accumulation of sphingolipids in multiple organ systems, including the heart. Cardiac involvement accounts for > 50% of AFD-related mortality and is a primary determinant of disease prognosis. AFD cardiomyopathy is heterogenous with key features that include left ventricular hypertrophy, conduction disturbances, myocardial fibrosis and valvular disease. Early diagnosis and treatment are crucial to prevent progressive and irreversible myocardial damage. Electrocardiography and echocardiography are effective and inexpensive first-line modalities to detect abnormalities that suggest cardiac involvement in patients with AFD. However, cardiovascular magnetic resonance imaging (CMR) can provide a more comprehensive assessment of myocardial tissue characteristics and cardiac structure and function. Recent studies have strengthened the role of T1 mapping, myocardial strain and late gadolinium enhancement using CMR in the assessment of patients with AFD. Whilst CMR is less widely available than electrocardiography and echocardiography, it has the potential to improve the diagnosis, monitoring and prognostication of patients with AFD. In the future, advanced CMR techniques may further refine risk stratification, guide therapeutic decisions and facilitate earlier interventions that can ultimately improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.